April Journal-2009.p65 - Association of Biotechnology and Pharmacy
April Journal-2009.p65 - Association of Biotechnology and Pharmacy
April Journal-2009.p65 - Association of Biotechnology and Pharmacy
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Current Trends in <strong>Biotechnology</strong> <strong>and</strong> <strong>Pharmacy</strong><br />
Vol. 3 (2) 181-187, <strong>April</strong> 2009. ISSN 0973-8916<br />
each genotype to develop disease. Differences<br />
in genotype frequency distribution between<br />
disease <strong>and</strong> control groups was done using 2*2<br />
χ2 <strong>and</strong> χ2 test for heterogeneity.<br />
Results <strong>and</strong> Discussion<br />
The cytochrome P450 (CYP) catalyzes<br />
the metabolism <strong>of</strong> numerous exogenous <strong>and</strong><br />
endogenous molecules. CYP3A5 was found to<br />
be more efficient in activating aflotoxin B1 to<br />
carcinogenic form (9). CYP3A5 was considered<br />
as a c<strong>and</strong>idate gene for prostate cancer as the<br />
expression was observed in both normal as well<br />
as in tumor tissue, whereas CYP3A4 expression<br />
was limited to normal prostate tissue. The<br />
hypothesis that prostate cancer risk might be<br />
associated with CYP3A5 genotype had been<br />
strengthened by the report <strong>of</strong> linkage<br />
183<br />
disequilibrium between CYP3A5 <strong>and</strong> CYP3A4<br />
alleles (10). The proportion <strong>of</strong> CYP3A4*1B <strong>and</strong><br />
CYP3A5*1 alleles was found to be increased in<br />
liver, gastric <strong>and</strong> colorectal cancer patients (11)<br />
<strong>and</strong> these findings were in accordance with other<br />
studies from Caucasian population (12).<br />
In the present study, the frequency <strong>of</strong><br />
heterozygotes for CYP3A5*1 (1/3) was<br />
significantly increased in breast cancer (53.0%)<br />
when compared to controls (41.4%) with<br />
corresponding increase in 3A5*1 allele frequency<br />
(Table 1). The study group showed deviation from<br />
Hardy-Weinberg equilibrium but not controls<br />
(÷2=0.58) indicating selective forces operating in<br />
disease group (÷2=5.09*) (Table 1). The<br />
frequency <strong>of</strong> CYP3A5*3 allele was found to be<br />
similar in both leukemia (CML, AML) group <strong>and</strong><br />
controls (7). Nogal et al (13) had reported that<br />
Table 1. CYP3A5*3 polymorphism with respect to breast cancer <strong>and</strong> epidemiological parameters<br />
Parameters 1/1 1/3 3/3 Allele<br />
Frequency<br />
n % n % n % 1 3<br />
Disease (249) 25 10.0 132 53.0 92 37.0 0.37 0.63<br />
Controls (249) 28 11.2 103 41.4 118 47.4 0.32 0.68<br />
Menopausal Status<br />
Premenopausal (124) 10 8.1 72 58.1 42 33.9 0.37 0.63<br />
Postmenopausal (125) 15 12.0 60 48.0 50 40.0 0.36 0.64<br />
Familial History<br />
Familial (74) 2 2.7 32 43.2 40 54.1 0.24 0.76<br />
Non-Familial (176) 2 1.1 70 39.8 104 59.1 0.21 0.79<br />
BMI<br />
30 (45) 4 8.9 21 46.7 20 44.5 0.32 0.68<br />
Occupation<br />
Housewives (173) 2 1.2 66 38.2 105 60.7 0.20 0.80<br />
Agriculture (27) 0 0 15 55.6 12 44.4 0.28 0.72<br />
White-Collar Jobs (43) 2 4.7 17 39.5 24 55.8 0.24 0.76<br />
Others (7) 0 0 4 57.1 3 42.9 0.21 0.79<br />
CYP3A5*3 <strong>and</strong> CYP3A5*6 Polymorphisms <strong>and</strong> Breast Cancer